Detailansicht

Wissensnetz

Person

Alfred Zippelius (1969-)

Arzt

Name	Alfred Zippelius
Zeit	1969- (Lebensdaten)
Ort	Schweiz
Beruf	Arzt (charakteristischer Beruf)
Variante	Alfred Karl Josef Zippelius
Beziehung	Universität Basel
Weitere Angaben	Diss. Medizinische Fakultät
Quelle	Internet: https://www.unispital-basel.ch/zuweiser/services/aerztinnen-und-aerzte-von-a-bis-z/x-y-z/pers/alfred-zippelius/ (Stand: 21.09.2020)
Datensatztyp	Person
GND-Nummer	121560910
Datensatz-ID	121560910
Beteiligt an alle anzeigen Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2 Corticosteroid-resistant immune-related adverse events: a systematic review Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX) Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle Onkologie Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions PD-L1 inhibitors in cancer immunotherapy : exploring the principles of PD-L1/PD-1 pathway inhibition in the treatment of cancer Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer Reverse Transkriptase-Polymerasekettenreaktion und immunzytochemischer Nachweis minimal residualer Tumorzellen : eine vergleichende Untersuchung

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Alfred Zippelius (1969-)

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2

Corticosteroid-resistant immune-related adverse events: a systematic review

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion

PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade

Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX)

Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle

Onkologie

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions

PD-L1 inhibitors in cancer immunotherapy : exploring the principles of PD-L1/PD-1 pathway inhibition in the treatment of cancer

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

Reverse Transkriptase-Polymerasekettenreaktion und immunzytochemischer Nachweis minimal residualer Tumorzellen : eine vergleichende Untersuchung